Home >> General Pharmaceuticals >> Housing >> Food & Beverage >>

Premature Labor (Tocolysis) - Pipeline Review, H1 2015

Published: Jan-2015 | Format: PDF | Global Markets Direct | Number of pages: 46 | Code: MRS - 18139


Global Markets Directs, Premature Labor (Tocolysis) Pipeline Review, H1 2015, provides an overview of the Premature Labor (Tocolysis)s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Premature Labor (Tocolysis), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Premature Labor (Tocolysis) and special features on late-stage and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Scope

The report provides a snapshot of the global therapeutic landscape of Premature Labor (Tocolysis)
The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
The report reviews key players involved in the therapeutics development for Premature Labor (Tocolysis) and enlists all their major and minor projects
The report summarizes all the dormant and discontinued pipeline projects 
A review of the Premature Labor (Tocolysis) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
A detailed assessment of monotherapy and combination therapy pipeline projects
Coverage of the Premature Labor (Tocolysis) pipeline on the basis of target, MoA, route of administration and molecule type
Latest news and deals relating related to pipeline products

Reasons to buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
Develop strategic initiatives by understanding the focus areas of leading companies
Identify and understand important and diverse types of therapeutics under development for Premature Labor (Tocolysis)
Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
Devise corrective measures for pipeline projects by understanding Premature Labor (Tocolysis) pipeline depth and focus of Indication therapeutics
Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table Of Content

Table of Contents 2
List of Tables 4
List of Figures 4

Introduction 5
Global Markets Direct Report Coverage 5
Premature Labor (Tocolysis) Overview 6
Therapeutics Development 7
Pipeline Products for Premature Labor (Tocolysis) - Overview 7
Pipeline Products for Premature Labor (Tocolysis) - Comparative Analysis 8
Premature Labor (Tocolysis) - Therapeutics under Development by Companies 9
Premature Labor (Tocolysis) - Therapeutics under Investigation by Universities/Institutes 10
Premature Labor (Tocolysis) - Pipeline Products Glance 11
Late Stage Products 11
Clinical Stage Products 12
Early Stage Products 13
Unknown Stage Products 14
Premature Labor (Tocolysis) - Products under Development by Companies 15
Premature Labor (Tocolysis) - Products under Investigation by Universities/Institutes 16
Premature Labor (Tocolysis) - Companies Involved in Therapeutics Development 17
Actavis plc 17
GlaxoSmithKline plc 18
Kissei Pharmaceutical Co., Ltd. 19
ObsEva SA 20
Premature Labor (Tocolysis) - Therapeutics Assessment 21
Assessment by Monotherapy Products 21
Assessment by Target 22
Assessment by Mechanism of Action 24
Assessment by Route of Administration 26
Assessment by Molecule Type 28
Drug Profiles 30
AT-814 - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
bedoradrine sulfate - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
Drug for Postpartum Depression and Premature Labor - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
OBE-001 - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
OBE-002 - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
Progesterone Second Generation - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
retosiban - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
Small Molecule to Agonize Progesterone Receptor for Preterm Birth - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
Premature Labor (Tocolysis) - Recent Pipeline Updates 39
Premature Labor (Tocolysis) - Dormant Projects 41
Premature Labor (Tocolysis) - Discontinued Products 42
Premature Labor (Tocolysis) - Product Development Milestones 43
Featured News & Press Releases 43
Aug 17, 2007: MediciNova Reports Phase Ib Clinical Study Results For MN-221 A Novel Treatment For Preterm Labor 43
Mar 14, 2005: MediciNova Initiates A Phase I Clinical Trial With MN-221 43
Mar 24, 2004: MediciNova Acquires Phase II Premature Labor Compound 44

Appendix 45
Methodology 45
Coverage 45
Secondary Research 45
Primary Research 45
Expert Panel Validation 45
Contact Us 45
Disclaimer 46

List of Tables

Number of Products under Development for Premature Labor (Tocolysis), H1 2015 7
Number of Products under Development for Premature Labor (Tocolysis) - Comparative Analysis, H1 2015 8
Number of Products under Development by Companies, H1 2015 9
Number of Products under Investigation by Universities/Institutes, H1 2015 10
Comparative Analysis by Late Stage Development, H1 2015 11
Comparative Analysis by Clinical Stage Development, H1 2015 12
Comparative Analysis by Early Stage Development, H1 2015 13
Comparative Analysis by Unknown Stage Development, H1 2015 14
Products under Development by Companies, H1 2015 15
Products under Investigation by Universities/Institutes, H1 2015 16
Premature Labor (Tocolysis) - Pipeline by Actavis plc, H1 2015 17
Premature Labor (Tocolysis) - Pipeline by GlaxoSmithKline plc, H1 2015 18
Premature Labor (Tocolysis) - Pipeline by Kissei Pharmaceutical Co., Ltd., H1 2015 19
Premature Labor (Tocolysis) - Pipeline by ObsEva SA, H1 2015 20
Assessment by Monotherapy Products, H1 2015 21
Number of Products by Stage and Target, H1 2015 23
Number of Products by Stage and Mechanism of Action, H1 2015 25
Number of Products by Stage and Route of Administration, H1 2015 27
Number of Products by Stage and Molecule Type, H1 2015 29
Premature Labor (Tocolysis) Therapeutics - Recent Pipeline Updates, H1 2015 39
Premature Labor (Tocolysis) - Dormant Projects, H1 2015 41
Premature Labor (Tocolysis) - Discontinued Products, H1 2015 42
 

List of Figures

Number of Products under Development for Premature Labor (Tocolysis), H1 2015 7
Number of Products under Development for Premature Labor (Tocolysis) - Comparative Analysis, H1 2015 8
Number of Products under Development by Companies, H1 2015 9
Comparative Analysis by Clinical Stage Development, H1 2015 12
Comparative Analysis by Early Stage Products, H1 2015 13
Assessment by Monotherapy Products, H1 2015 21
Number of Products by Top 10 Targets, H1 2015 22
Number of Products by Stage and Top 10 Targets, H1 2015 23
Number of Products by Top 10 Mechanism of Actions, H1 2015 24
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 24
Number of Products by Top 10 Routes of Administration, H1 2015 26
Number of Products by Stage and Top 10 Routes of Administration, H1 2015 27
Number of Products by Top 10 Molecule Types, H1 2015 28
Number of Products by Stage and Top 10 Molecule Types, H1 2015 29

Inquiry For Buying

Please fill your details below, to inquire about this report:
Indicates required fields

Request Sample

Please fill your details below, to receive sample report:
Indicates required fields

  • Payment Mode

COVID-19 Pandemic Impacts

Our Analysts and Consultants are working ceaselessly to congregate, identify, analyze, and portray the Actual Impacts of COVID-19 Global Pandemic in each of our published as well as ongoing research reports to Redefine and Revise Current and Future Market Trends, Growth Rates, And Market Size Projections across the Globe as well as in different Regions and individual Countries.

Single User | $(USD)2000 View Pricing